Related Experiment Video
Updated: Mar 7, 2026

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
Published on: January 7, 2019
Abstract:
▼Daclizumab (Zinbryta-Biogen Idec) is a new injectable disease-modifying drug licensed for the treatment of relapsing forms of multiple sclerosis (MS) in adults.1 It is a humanised monoclonal antibody that modulates interleukin-2 signalling.1-3 Here, we review the evidence on daclizumab and consider its place in the management of MS.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...

